Global Point of Care Molecular Diagnosis Market
Global Point of Care Molecular Diagnosis Market

Point of Care Molecular Diagnosis Comprehensive Study by End Use (Physician Offices, Health Department Clinics, Pharmacy Clinics, Others), Product (Assays & Kits, Instruments/Analysers, Services & Software), Tests (RT-PCR, INAAT, Others) Players and Region - Global Market Outlook to 2026

Point of Care Molecular Diagnosis Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Sep 2021 Edition 243 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Point of Care Molecular Diagnosis Market Scope?
Point of Care Molecular allows a physician to make a diagnosis or rule out a diagnosis and treat a patient while they are still in the clinic. Furthermore, as compared to rapid antigen detection tests, molecular assays have shown better sensitivity, removing the need for secondary confirmation of negative results and leading to much more appropriate antibiotic administration, including the avoidance of antibiotic use for viral infections.

The Point of Care Molecular Diagnosis market study is being classified and major geographies with country level break-up.

The demand for POC Molecular Diagnostics is increasing with each passing day. The businesses in this industry facing major competition on a global scale with leading players of the market who hold a major market share. The Leading Players are engaged in organic and non-organic strategic global expansion to maintain their Market Position. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Point of Care Molecular Diagnosis market throughout the predicted period.

Roche (Switzerland), Abbott Laboratories (United States), Biomerieux (France), Danaher (United States), Roche diagnostics (Switzerland), Meridian biosciences (United States), Quidel (United States), Sanofi (France), Merck (United States) and Johnson and Johnson (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Cardea (United States), Inflammatix (United States) and Sherlock Biosciences (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Point of Care Molecular Diagnosis market by Type, Application and Region.

On the basis of geography, the market of Point of Care Molecular Diagnosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their development strategies
In March 2021 Roche Released a Statement Stating the Acquisition of Genmark. The ePlex technology from GenMark provides clinicians with quick and actionable findings, allowing them to pinpoint the source of infection and the most effective therapy, potentially saving lives and reducing healthcare costs. Roche's diagnostic portfolio has been enhanced by the integration of GenMark's unique multiplex technology, which addresses a wide range of infectious disease testing needs, including respiratory and bloodstream infections.



Influencing Market Trend
  • The Rise in CLIA-Waived Molecular POC Tests

Market Drivers
  • Microfluidics and Other Instrumentation Technologies That Allow for the Creation of Low-Cost Platforms and Tests

Opportunities
  • In Resource-Constrained Environments, Molecular POCT is Becoming Increasingly Beneficial

Restraints
  • Time-Consuming and Stringent Government Regulations and Policies

Challenges
  • Direct Interaction With a Patient During Specimen Collection Poses the Highest Danger


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Government Regulatory and Research Organizations, Healthcare Organization, Pharmaceutical Companies and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Frequently Asked Questions (FAQ):

1. At what growth rate would the Point of Care Molecular Diagnosis market expands?
The Global Point of Care Molecular Diagnosis market is expected to see a growth of % during projected year 2020 to 2026.

2. Who are the prominent players of the Global Point of Care Molecular Diagnosis market?
The prominent players of Global Point of Care Molecular Diagnosis market are Roche (Switzerland), Abbott Laboratories (United States), Biomerieux (France), Danaher (United States), Roche diagnostics (Switzerland), Meridian biosciences (United States), Quidel (United States), Sanofi (France), Merck (United States) and Johnson and Johnson (United States), to name a few.

3. What are the top priorities to focus for Point of Care Molecular Diagnosis marketís growth?
In this highly competitive & fast evolving Point of Care Molecular Diagnosis industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.
Report Objectives / Segmentation Covered
By End Use
  • Physician Offices
  • Health Department Clinics
  • Pharmacy Clinics
  • Others

By Product
  • Assays & Kits
  • Instruments/Analysers
  • Services & Software

By Tests
  • RT-PCR
  • INAAT
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Microfluidics and Other Instrumentation Technologies That Allow for the Creation of Low-Cost Platforms and Tests
    • 3.3. Market Challenges
      • 3.3.1. Direct Interaction With a Patient During Specimen Collection Poses the Highest Danger
    • 3.4. Market Trends
      • 3.4.1. The Rise in CLIA-Waived Molecular POC Tests
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Point of Care Molecular Diagnosis, by End Use, Product, Tests and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Point of Care Molecular Diagnosis (Value)
      • 5.2.1. Global Point of Care Molecular Diagnosis by: End Use (Value)
        • 5.2.1.1. Physician Offices
        • 5.2.1.2. Health Department Clinics
        • 5.2.1.3. Pharmacy Clinics
        • 5.2.1.4. Others
      • 5.2.2. Global Point of Care Molecular Diagnosis by: Product (Value)
        • 5.2.2.1. Assays & Kits
        • 5.2.2.2. Instruments/Analysers
        • 5.2.2.3. Services & Software
      • 5.2.3. Global Point of Care Molecular Diagnosis by: Tests (Value)
        • 5.2.3.1. RT-PCR
        • 5.2.3.2. INAAT
        • 5.2.3.3. Others
      • 5.2.4. Global Point of Care Molecular Diagnosis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Point of Care Molecular Diagnosis (Price)
  • 6. Point of Care Molecular Diagnosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biomerieux (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Danaher (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche diagnostics (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Meridian biosciences (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Quidel (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson and Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Point of Care Molecular Diagnosis Sale, by End Use, Product, Tests and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Point of Care Molecular Diagnosis (Value)
      • 7.2.1. Global Point of Care Molecular Diagnosis by: End Use (Value)
        • 7.2.1.1. Physician Offices
        • 7.2.1.2. Health Department Clinics
        • 7.2.1.3. Pharmacy Clinics
        • 7.2.1.4. Others
      • 7.2.2. Global Point of Care Molecular Diagnosis by: Product (Value)
        • 7.2.2.1. Assays & Kits
        • 7.2.2.2. Instruments/Analysers
        • 7.2.2.3. Services & Software
      • 7.2.3. Global Point of Care Molecular Diagnosis by: Tests (Value)
        • 7.2.3.1. RT-PCR
        • 7.2.3.2. INAAT
        • 7.2.3.3. Others
      • 7.2.4. Global Point of Care Molecular Diagnosis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Point of Care Molecular Diagnosis (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Point of Care Molecular Diagnosis: by End Use(USD Million)
  • Table 2. Point of Care Molecular Diagnosis Physician Offices , by Region USD Million (2015-2020)
  • Table 3. Point of Care Molecular Diagnosis Health Department Clinics , by Region USD Million (2015-2020)
  • Table 4. Point of Care Molecular Diagnosis Pharmacy Clinics , by Region USD Million (2015-2020)
  • Table 5. Point of Care Molecular Diagnosis Others , by Region USD Million (2015-2020)
  • Table 6. Point of Care Molecular Diagnosis: by Product(USD Million)
  • Table 7. Point of Care Molecular Diagnosis Assays & Kits , by Region USD Million (2015-2020)
  • Table 8. Point of Care Molecular Diagnosis Instruments/Analysers , by Region USD Million (2015-2020)
  • Table 9. Point of Care Molecular Diagnosis Services & Software , by Region USD Million (2015-2020)
  • Table 10. Point of Care Molecular Diagnosis: by Tests(USD Million)
  • Table 11. Point of Care Molecular Diagnosis RT-PCR , by Region USD Million (2015-2020)
  • Table 12. Point of Care Molecular Diagnosis INAAT , by Region USD Million (2015-2020)
  • Table 13. Point of Care Molecular Diagnosis Others , by Region USD Million (2015-2020)
  • Table 14. South America Point of Care Molecular Diagnosis, by Country USD Million (2015-2020)
  • Table 15. South America Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 16. South America Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 17. South America Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 18. Brazil Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 19. Brazil Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 20. Brazil Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 21. Argentina Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 22. Argentina Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 23. Argentina Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 24. Rest of South America Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 25. Rest of South America Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 26. Rest of South America Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 27. Asia Pacific Point of Care Molecular Diagnosis, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 29. Asia Pacific Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 30. Asia Pacific Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 31. China Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 32. China Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 33. China Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 34. Japan Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 35. Japan Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 36. Japan Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 37. India Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 38. India Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 39. India Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 40. South Korea Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 41. South Korea Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 42. South Korea Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 43. Taiwan Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 44. Taiwan Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 45. Taiwan Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 46. Australia Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 47. Australia Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 48. Australia Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 52. Europe Point of Care Molecular Diagnosis, by Country USD Million (2015-2020)
  • Table 53. Europe Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 54. Europe Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 55. Europe Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 56. Germany Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 57. Germany Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 58. Germany Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 59. France Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 60. France Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 61. France Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 62. Italy Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 63. Italy Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 64. Italy Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 65. United Kingdom Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 66. United Kingdom Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 67. United Kingdom Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 68. Netherlands Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 69. Netherlands Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 70. Netherlands Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 71. Rest of Europe Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 72. Rest of Europe Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 73. Rest of Europe Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 74. MEA Point of Care Molecular Diagnosis, by Country USD Million (2015-2020)
  • Table 75. MEA Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 76. MEA Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 77. MEA Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 78. Middle East Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 79. Middle East Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 80. Middle East Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 81. Africa Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 82. Africa Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 83. Africa Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 84. North America Point of Care Molecular Diagnosis, by Country USD Million (2015-2020)
  • Table 85. North America Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 86. North America Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 87. North America Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 88. United States Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 89. United States Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 90. United States Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 91. Canada Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 92. Canada Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 93. Canada Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 94. Mexico Point of Care Molecular Diagnosis, by End Use USD Million (2015-2020)
  • Table 95. Mexico Point of Care Molecular Diagnosis, by Product USD Million (2015-2020)
  • Table 96. Mexico Point of Care Molecular Diagnosis, by Tests USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Point of Care Molecular Diagnosis: by End Use(USD Million)
  • Table 108. Point of Care Molecular Diagnosis Physician Offices , by Region USD Million (2021-2026)
  • Table 109. Point of Care Molecular Diagnosis Health Department Clinics , by Region USD Million (2021-2026)
  • Table 110. Point of Care Molecular Diagnosis Pharmacy Clinics , by Region USD Million (2021-2026)
  • Table 111. Point of Care Molecular Diagnosis Others , by Region USD Million (2021-2026)
  • Table 112. Point of Care Molecular Diagnosis: by Product(USD Million)
  • Table 113. Point of Care Molecular Diagnosis Assays & Kits , by Region USD Million (2021-2026)
  • Table 114. Point of Care Molecular Diagnosis Instruments/Analysers , by Region USD Million (2021-2026)
  • Table 115. Point of Care Molecular Diagnosis Services & Software , by Region USD Million (2021-2026)
  • Table 116. Point of Care Molecular Diagnosis: by Tests(USD Million)
  • Table 117. Point of Care Molecular Diagnosis RT-PCR , by Region USD Million (2021-2026)
  • Table 118. Point of Care Molecular Diagnosis INAAT , by Region USD Million (2021-2026)
  • Table 119. Point of Care Molecular Diagnosis Others , by Region USD Million (2021-2026)
  • Table 120. South America Point of Care Molecular Diagnosis, by Country USD Million (2021-2026)
  • Table 121. South America Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 122. South America Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 123. South America Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 124. Brazil Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 125. Brazil Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 126. Brazil Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 127. Argentina Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 128. Argentina Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 129. Argentina Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 130. Rest of South America Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 131. Rest of South America Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 132. Rest of South America Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 133. Asia Pacific Point of Care Molecular Diagnosis, by Country USD Million (2021-2026)
  • Table 134. Asia Pacific Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 135. Asia Pacific Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 136. Asia Pacific Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 137. China Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 138. China Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 139. China Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 140. Japan Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 141. Japan Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 142. Japan Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 143. India Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 144. India Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 145. India Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 146. South Korea Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 147. South Korea Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 148. South Korea Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 149. Taiwan Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 150. Taiwan Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 151. Taiwan Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 152. Australia Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 153. Australia Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 154. Australia Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 158. Europe Point of Care Molecular Diagnosis, by Country USD Million (2021-2026)
  • Table 159. Europe Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 160. Europe Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 161. Europe Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 162. Germany Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 163. Germany Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 164. Germany Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 165. France Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 166. France Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 167. France Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 168. Italy Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 169. Italy Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 170. Italy Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 171. United Kingdom Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 172. United Kingdom Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 173. United Kingdom Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 174. Netherlands Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 175. Netherlands Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 176. Netherlands Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 177. Rest of Europe Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 178. Rest of Europe Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 179. Rest of Europe Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 180. MEA Point of Care Molecular Diagnosis, by Country USD Million (2021-2026)
  • Table 181. MEA Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 182. MEA Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 183. MEA Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 184. Middle East Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 185. Middle East Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 186. Middle East Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 187. Africa Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 188. Africa Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 189. Africa Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 190. North America Point of Care Molecular Diagnosis, by Country USD Million (2021-2026)
  • Table 191. North America Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 192. North America Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 193. North America Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 194. United States Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 195. United States Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 196. United States Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 197. Canada Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 198. Canada Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 199. Canada Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 200. Mexico Point of Care Molecular Diagnosis, by End Use USD Million (2021-2026)
  • Table 201. Mexico Point of Care Molecular Diagnosis, by Product USD Million (2021-2026)
  • Table 202. Mexico Point of Care Molecular Diagnosis, by Tests USD Million (2021-2026)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Point of Care Molecular Diagnosis: by End Use USD Million (2015-2020)
  • Figure 5. Global Point of Care Molecular Diagnosis: by Product USD Million (2015-2020)
  • Figure 6. Global Point of Care Molecular Diagnosis: by Tests USD Million (2015-2020)
  • Figure 7. South America Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 8. Asia Pacific Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 9. Europe Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 10. MEA Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 11. North America Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 12. Global Point of Care Molecular Diagnosis share by Players 2020 (%)
  • Figure 13. Global Point of Care Molecular Diagnosis share by Players (Top 3) 2020(%)
  • Figure 14. Global Point of Care Molecular Diagnosis share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Roche (Switzerland) Revenue: by Geography 2020
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 20. Biomerieux (France) Revenue, Net Income and Gross profit
  • Figure 21. Biomerieux (France) Revenue: by Geography 2020
  • Figure 22. Danaher (United States) Revenue, Net Income and Gross profit
  • Figure 23. Danaher (United States) Revenue: by Geography 2020
  • Figure 24. Roche diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Roche diagnostics (Switzerland) Revenue: by Geography 2020
  • Figure 26. Meridian biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 27. Meridian biosciences (United States) Revenue: by Geography 2020
  • Figure 28. Quidel (United States) Revenue, Net Income and Gross profit
  • Figure 29. Quidel (United States) Revenue: by Geography 2020
  • Figure 30. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 31. Sanofi (France) Revenue: by Geography 2020
  • Figure 32. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 33. Merck (United States) Revenue: by Geography 2020
  • Figure 34. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson and Johnson (United States) Revenue: by Geography 2020
  • Figure 36. Global Point of Care Molecular Diagnosis: by End Use USD Million (2021-2026)
  • Figure 37. Global Point of Care Molecular Diagnosis: by Product USD Million (2021-2026)
  • Figure 38. Global Point of Care Molecular Diagnosis: by Tests USD Million (2021-2026)
  • Figure 39. South America Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 40. Asia Pacific Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 41. Europe Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 42. MEA Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 43. North America Point of Care Molecular Diagnosis Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Roche (Switzerland)
  • Abbott Laboratories (United States)
  • Biomerieux (France)
  • Danaher (United States)
  • Roche diagnostics (Switzerland)
  • Meridian biosciences (United States)
  • Quidel (United States)
  • Sanofi (France)
  • Merck (United States)
  • Johnson and Johnson (United States)
Additional players considered in the study are as follows:
Cardea (United States) , Inflammatix (United States) , Sherlock Biosciences (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation